{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:56:49Z","timestamp":1790575009621,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:00:00Z","timestamp":1790467200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"abstract":"<jats:p>\n                    Long\u2010acting intramuscular cabotegravir\/rilpivirine (LA CAB\/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49\u2010year\u2010old man with virologically suppressed HIV\u20101 infection receiving LA CAB\/RPV every 8\u00a0weeks who was treated with rifampicin 600\u2009mg twice daily combined with levofloxacin for 7\u00a0days as methicillin\u2010resistant\n                    <jats:styled-content style=\"fixed-case\">\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                    <\/jats:styled-content>\n                    eradication therapy. Temporary oral bridging therapy with tenofovir disoproxil fumarate\/emtricitabine and dolutegravir was started concurrently. Plasma cabotegravir (CAB) and rilpivirine (RPV) concentrations were measured weekly using validated LC\u2010MS\/MS. Prior to rifampicin initiation, plasma concentrations were 2.08\u2009mg\/L for CAB and 0.126\u2009mg\/L for RPV and therefore well above target C\n                    <jats:sub>trough<\/jats:sub>\n                    levels of &gt;0.664\u2009mg\/L for CAB and &gt;0.032\u2009mg\/L for RPV. After 7\u00a0days of rifampicin treatment, concentrations decreased to 0.90\u2009mg\/L for CAB and 0.022\u2009mg\/L for RPV, corresponding to reductions of 57% and 83%, respectively, with RPV concentrations falling below the proposed therapeutic target. One week after rifampicin discontinuation, concentrations recovered to 1.10\u00a0mg\/L for CAB and 0.050\u2009mg\/L for RPV. The concentrations increased further thereafter without additional drug administration, reflecting continued release from the intramuscular depot. HIV\u20101 RNA remained undetectable throughout follow\u2010up. The observed reduction in RPV exposure exceeded previous physiologically based pharmacokinetic model predictions for intramuscular RPV. This case provides a pharmacokinetic rationale for more nuanced management of short\u2010term enzyme induction in people with HIV receiving LA ART and may help inform future clinical guidance.\n                  <\/jats:p>","DOI":"10.1002\/bcp.70856","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:33:37Z","timestamp":1790573617000},"source":"Crossref","is-referenced-by-count":0,"title":["Rapid onset and offset of the interaction between rifampicin and long\u2010acting cabotegravir\/rilpivirine: A pharmacokinetic case report"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-7933","authenticated-orcid":false,"given":"Emilie M.","family":"Gieling","sequence":"first","affiliation":[{"name":"Department of Pharmacy University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne A. H.","family":"Bevers","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy Catharina Hospital  Eindhoven The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter L.","family":"Smit","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Division of Virology University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8149-5191","authenticated-orcid":false,"given":"Rosa H.","family":"Elias","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelies","family":"Verbon","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7279-2818","authenticated-orcid":false,"given":"David M.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Pharmacology, and Toxicology Radboud University Medical Center  Nijmegen the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berend J.","family":"van Welzen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases University Medical Center Utrecht  Utrecht the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(20)30340\u20104"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70120"},{"key":"e_1_2_7_4_1","unstructured":"European Medicines Agency.Vocabria: EPAR\u2014product information. European Medicines Agency. Accessed July 10 2026.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/vocabria\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_7_5_1","unstructured":"European Medicines Agency.Rekambys: EPAR\u2014product information. European Medicines Agency. Accessed July 10 2026.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/rekambys\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508228"},{"key":"e_1_2_7_7_1","unstructured":"European Medicines Agency.Edurant: EPAR\u2014product information. European Medicines Agency. Accessed July 10 2026.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/edurant\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00487\u201017"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac901"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy726"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010021\u201001005\u20101"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad604"},{"key":"e_1_2_7_13_1","unstructured":"World Health Organization.WHO updated recommendations on HIV clinical management: recommendations for a public health approach. World Health Organization.2025. Accessed August 7 2026.https:\/\/www.who.int\/publications\/i\/item\/9789240119468"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088\u2010200342090\u201000003"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115832"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae023"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00683\u201023"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103018(21)00184\u20103"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010025\u201010593\u20103"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70856","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:33:39Z","timestamp":1790573619000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,27]]},"references-count":19,"alternative-id":["10.1002\/bcp.70856"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70856","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,27]]},"article-number":"bcp.70856"}}